XML 36 R75.htm IDEA: XBRL DOCUMENT v2.4.0.6
Commitments and Contingencies (Details Textual)
 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended
Jul. 31, 2006
Claim
Dec. 31, 2012
USD ($)
Dec. 31, 2011
USD ($)
Dec. 31, 2010
USD ($)
Sep. 30, 2010
Caliper Life Sciences [Member]
USD ($)
sqft
Dec. 31, 2012
Caliper Life Sciences [Member]
Dec. 31, 2011
BMR-Gateway Boulevard LLC [Member]
USD ($)
Dec. 31, 2010
BMR-Gateway Boulevard LLC [Member]
USD ($)
sqft
Dec. 31, 2012
BMR-Gateway Boulevard LLC [Member]
USD ($)
sqft
Dec. 31, 2012
Scientific and Administrative Facility [Member]
USD ($)
Jan. 31, 2011
Stem Cell Sciences UK [Member]
GBP (£)
sqft
Dec. 31, 2012
Stem Cell Sciences UK [Member]
USD ($)
Commitments and Contingencies (Textual) [Abstract]                        
Term of lease         2 years   11 years 6 months     15 years    
Rent over term of lease         $ 1,081,000     $ 17,869,000        
Deferred rent under sublease agreement     2,603       1,301,000   1,389,000 249,000    
Additional area of facility                 30,000      
Area of leased space                     5,000  
Area of lease reduced                     1,900  
Rental payments                     61,000  
Annual payments                       50,000
Letter of credit as security deposit withdrawn on expiration of lease for Palo Alto facility     389,000                  
Square feet area of office and lab space under lease         13,200     43,000        
Useful life                       14 years
Litigation costs                       700,000
Royalty payments                       600,000
Lease term expires   Aug. 31, 2011       Sep. 30, 2013       Jun. 30, 2013    
Sublease agreement           2 years            
Operating expenses   2,520,219 3,768,586 2,703,952                
Commitments and Contingencies (Additional Textual) [Abstract]                        
Proceeds from the issuance of industrial revenue bonds   5,000,000                    
Period of maturity   2014-08                    
Interest rate for remaining bond series   9.50%                    
Outstanding principal   374,000                    
Operating expenses   2,520,219 3,768,586 2,703,952                
Reducing lieu of cash payments   50,000                    
Payments creditable against royalties   $ 50,000                    
Number of patients violate claims of Neuralstem's activities 4